Tirzepatide
Tirzepatide
Metabolic & Endocrine
Tirzepatide is indexed as peptide therapeutic in the PeptideBase article library. It is referenced in “GLP-1 Peptides vs “Research Peptides”: What People Mean and Why It Matters” and 7 other PeptideBase articles. This page groups the relevant coverage; evidence strength, safety, and clinical relevance depend on the specific claim and source.
Deep Dives on Tirzepatide
Start here for the plain-English articles connected to this peptide.
FDA Warned Four Peptide Sellers at Once: What the September 2026 Letters Actually Say
FDA's four September 2026 peptide seller warning letters show why research-only disclaimers did not outweigh human-drug claims, bacteriostatic water, guides, calculators, and other injection-related sales context.
Read articleTE-8105: What a 38-Person First-in-Human Long-Acting GLP-1 Trial Actually Shows
TE-8105 had an approximately 120-hour half-life in a 38-person open-label Phase 1 study. Here is what that finding—and the early weight and safety observations—can and cannot establish.
Read articleGIP Agonism vs Antagonism: Why Opposite Strategies Can Both Reduce Food Intake in Mice
A 2026 mouse study suggests GIPR agonism and antagonism can affect food intake and body weight through distinct brain regions—not interchangeable mechanisms.
Read articleDo GLP-1 Drugs Cause Hair Loss? What the New BMJ Study Actually Shows
A 2026 BMJ target-trial emulation found a low-frequency association between GLP-1 receptor agonists and non-scarring alopecia in adults with type 2 diabetes, but it did not prove causation.
Read articlePeptides for Long COVID: What Is Being Studied—and What Is Only Being Marketed
No peptide is proven to treat Long COVID. Separate controlled trials of tirzepatide and larazotide from planned research, animal studies, anecdotes, and marketing.
Read articleGLP-1 Side Effects: What Trials, Labels, and Online Communities Can Each Tell Us
GLP-1 side-effect claims mean different things depending on whether they come from clinical trials, FDA labels, adverse-event databases, or online communities. This evidence-method guide explains how to read each source without turning anecdotes into proof or labels into panic.
Read articleIs Orforglipron a Peptide? The New Oral GLP-1 Pill Explained
Orforglipron is an oral, non-peptide small-molecule GLP-1 receptor agonist. This clarifier explains why people confuse it with peptide GLP-1 drugs and how FDA-approved Foundayo differs from research peptides.
Read articleGLP-1 Peptides vs “Research Peptides”: What People Mean and Why It Matters
A clear, evidence-aware guide to why GLP-1 drugs are peptides, how semaglutide and tirzepatide differ from vague research-peptide marketing, and why regulatory status matters.
Read articleQuick Facts
- Origin
- Named peptide therapeutic referenced in PeptideBase coverage
- Category
- Metabolic & Endocrine